Novo Lifts Full-Year Outlook as Wegovy Pill Demand Beats Expectations
NVO sits 19% above its 52-week low of $35.12.
Summary
Novo raised its full-year outlook to a range of -2% to +2% at constant exchange rates, a big step up from the prior guidance of declines of up to 6%. Q3 net sales came in at DKK 79.19B, up 6% year over year, while reported operating profit fell 3% to DKK 23B; adjusted operating profit rose 34% to DKK 31.7B and beat estimates. The Wegovy pill did the heavy lifting at DKK 5.39B in sales, above expectations, and management said it should reach more than 20 markets next year. Ozempic held up better than feared, which matters because this is the same GLP-1 franchise that has been under pressure from Eli Lilly's oral push. Separately, Novo named Luigi La Corte of Galderma to succeed CFO Karsten Munk Knudsen, who stays through the end of December. The guidance raise is the headline for traders: it resets the earnings floor after a year of cuts and puts the oral obesity race with Lilly back in focus.
At the time of this announcement, NVO was trading at $41.96 on NYSE in the Life Sciences sector, with a market capitalization of approximately $178.8B. The 52-week trading range was $35.12 to $64.16. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Seeking Alpha.